NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.57 +0.09 (+0.11%) GOLD FUTURES
2,322.40 -8.80 (-0.38%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
50,376.41 -261.25 (-0.52%)
Medivir AB (publ) (0GP7.L)
- PR Newswire
Resolutions at the Annual General Meeting in Medivir on 7 May 2024
Medivir Aktiebolag (publ) held its annual general meeting today on 7 May 2024. The annual general meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). The annual general meeting in Medivir Aktiebolag (publ) resolved the following:
- PR Newswire
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024
Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months.
- PR Newswire
Medivir brings the Q1 webcast forward to 10 a.m. on April 30
Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company will host the Q1 Quarterly Results webcast tomorrow, April 30, at 10 a.m. CET. The webcast is brought forward as Nasdaq Stockholm closes earlier.
